Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
Learn More
Medchemexpress LLC SOR-C13 TFA | 1187852-48-7 | 99.3% | 1565.81 (free acid) | 50 MG
Supplier: Medchemexpress LLC HYP1651A50MG
SOR-C13 TFA is a carboxy-terminal truncated peptide that acts as a high-affinity TRPV6 antagonist, exhibiting an IC50 value of 14 nM. TRPV6 is a non-voltage gated calcium channel implicated in malignancy and poor prognosis in breast cancer. This compound has demonstrated anticancer activity.
- High-affinity TRPV6 antagonist with an IC50 of 14 nM.
- TRPV6 is associated with malignancy and poor prognosis in breast cancer.
- Exhibits anticancer activity.
- In vivo studies showed effective inhibition of tumor growth in female NOD/SCID mice with SKOV-3 cells at dosages of 400, 600, and 800 mg/kg (IP; daily; on days 1 to 12).
- Has been investigated in clinical trials for cancer and advanced malignant solid neoplasm.
Product Title
By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.
Spot an opportunity for improvement?